RT Journal Article
SR Electronic
T1 Increased risk of infection with SARS-CoV-2 Omicron compared to Delta in vaccinated and previously infected individuals, the Netherlands, 22 November to 19 December 2021
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.12.20.21268121
DO 10.1101/2021.12.20.21268121
A1 Eggink, Dirk
A1 Andeweg, Stijn P.
A1 Vennema, Harry
A1 van Maarseveen, Noortje
A1 Vermaas, Klaas
A1 Vlaemynck, Boris
A1 Schepers, Raf
A1 van Gageldonk-Lafeber, Arianne B.
A1 van den Hof, Susan
A1 Reusken, Chantal B.E.M.
A1 Knol, Mirjam J.
YR 2021
UL http://medrxiv.org/content/early/2021/12/21/2021.12.20.21268121.abstract
AB Infections by the Omicron SARS-CoV-2 variant are rapidly increasing worldwide. Among 70,983 infected individuals (age ≥ 12 years), we observed an increased risk of S-gene target failure, predictive of the Omicron variant, in fully vaccinated (odds ratio: 5.0; 95% confidence interval: 4.0-6.1) and previously infected individuals (OR: 4.9: 95% CI: 3.1-7.7) compared with infected naïve individuals. This suggests a substantial decrease in protection from vaccine- or infection-induced immunity against SARS-CoV-2 infections caused by the Omicron variant compared with the Delta variant.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was funded by the Ministry of Health, Welfare and Sports (VWS).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Centre for Clinical Expertise at the RIVM assessed the research proposal following the specific conditions as stated in the law for medical research involving human subjects (WMO). In their opinion the research does not fulfill one or both of these conditions and therefore conclude it is exempted for further approval by the ethical research committee. Pathogen surveillance is a legal task of the RIVM (artikel 3 Wet RIVM, article 3 Law RIVM) and is carried out under the responsibility of the Minister of Health, Welfare and Sports (VWS). Article 6c (artikel 6c) of the Public Health Act (Wet Publieke Gezondheid) provides that RIVM may receive pseudonymised data for this task without individual consent of each case.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData produced in the present study are available upon reasonable request to the authors.